Professor A. Bardelli is the Chairman of Horizon's Scientific Advisory Board and continues to play an active role in the Company.

In 2014 Prof. Bardelli was listed in the Thomson Reuters List of Highly Cited Researchers. He is the author of over 150 peer-reviewed manuscripts (H factor 68). He is a Professor at the Department of Oncology, University of Torino, Director of the Laboratory of Molecular Oncology and deputy Director of the Candiolo Cancer Institute-IRCCS, Torino, Italy.

His work is aimed at developing precision medicines for cancer patients. As a postdoc at the Johns Hopkins University (USA), in the group led by Bert Vogelstein, he performed the first comprehensive mutational profile of kinases in colorectal cancers (CRC).

Professor Bardelli will serve on the EACR Board as President Elect during the Presidency of Anton Berns (Netherlands Cancer Institute) and will take up the role of President in July 2018 at the 25th Biennial Congress of the EACR.

See full release:

https://www.eacr.org/news/alberto-bardelli-named-president-elect-of-the-european-association-for-cancer-research

Horizon Discovery Group plc published this content on 13 September 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 13 September 2016 09:00:05 UTC.

Original documenthttps://www.horizondiscovery.com/about-us/news/horizon-discovery-co-founder-alberto-bardelli-named-president-elect-of-eacr

Public permalinkhttp://www.publicnow.com/view/2F238729AB7E148F1367F4DF3F631374D65CB7F2